💡 Dupilumab for ABPA: What You Need to Know Now the Trial Is Complete

A large Phase III trial—called LIBERTY‑ABPA AIRED—has recently completed studying dupilumab in people with ABPA and asthma who frequently exacerbate despite other treatments. Let’s break down what that means and what’s still missing 📌

🗓️ Trial Timeline & Scope

• Trial completed: Primary data collection finished in July 2023, study closed in February 2024. It enrolled around 170 patients from over 30 sites across several countries including the UK, EU, US, Canada, Japan, and more Wikipedia+15trialsummaries.com+15Clinical Trials Register+15.

• Design: Randomized, double‑blind, placebo‑controlled over 52 weeks, followed by 12 weeks safety follow‑up trialsummaries.comClinical Trials Register.

📋 What Was Measured?

The trial assessed:

• Severe respiratory exacerbations (requiring steroids or hospital admission)

• Lung function changes (e.g. FEV₁)

• ABPA-related symptoms, quality of life, asthma control

• Biomarkers including IgE and FeNO

• Safety and tolerability, including antibody formation to dupilumab Wikipedia+15Clinical Trials+15trialsummaries.com+15

🧬 Why Results Matter

Dupilumab blocks both IL‑4 and IL‑13 pathways, which drive inflammation, mucus, and elevated IgE in ABPA. Early case reports and small series have shown promising benefits, especially in reducing exacerbations and steroid use, but until now, no large randomized trial data were available ScienceDirect+1PMC+1.

❓ What’s Available Now?

• ✅ The trial has finished, but official results have not yet been published or released publicly.

• 🕒 Regulators and sponsors previously estimated publication around late 2023, with actual report likely still under review or preparation ctv.veeva.com+3ScienceDirect+3Clinical Trials+3.

• 📡 Until these results are public, dupilumab remains not officially approved for ABPA, though individual clinicians may consider off‑label use in select cases.

🧾 Summary Table: Where Things Stand

💬 What Should Patients Do Now?

If you’re managing ABPA and considering biologic options:

• ✅ Ask if longstanding biologics like dupilumab are being considered for your individual case.

• 💬 Be clear that formal approval for ABPA is still pending, pending public release of the trial results.

• 🩺 Consult with your specialist or asthma/respiratory team about possible off‑label use—they can explain access options, benefits, and risks.

🧭 Final Thoughts

The LIBERTY‑ABPA AIRED trial has now completed, marking a major milestone for potential new treatment in ABPA. But until results are published and reviewed, dupilumab remains off-label for this condition.

You may still hear about its use in ABPA from case reports showing positive outcomes—but wider clinical acceptance awaits published study data. If it becomes available, it could offer meaningful benefits—but only if confirmed in research.